Moreover, CD8+ and CD4+ T-cell densities in the tumour were identified as the two most optimised predictive biomarkers, consistent with observations by studies on single-agent PD-L1 blockade therapies [20,21]. The gene discussed is CD8A; the disease is neoplasm.